Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
|Articles|June 1, 2001
Surveys give insight to managed care contracts
For physicians faced with decision of which contracts to sign, help is available thanks to survey sent to managed care firms
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Trial Supports Risankizumab for Pediatric Psoriasis
2
Dermatology Times Monthly FDA and Pipeline Review: October 2026
3
Brepocitinib Clears Skin in 69% of Cutaneous Sarcoidosis Patients
4
Veradermics Reports Sustained Hair Growth With VDPHL01 at 1 Year
5